6885 Stock Overview
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BRIM Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$31.20 |
| 52 Week High | NT$87.80 |
| 52 Week Low | NT$24.60 |
| Beta | 0 |
| 1 Month Change | -2.95% |
| 3 Month Change | 8.90% |
| 1 Year Change | -59.74% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 22.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6885 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.7% | 2.0% | 4.0% |
| 1Y | -59.7% | -24.4% | 28.5% |
Return vs Industry: 6885 underperformed the TW Biotechs industry which returned -24.4% over the past year.
Return vs Market: 6885 underperformed the TW Market which returned 28.5% over the past year.
Price Volatility
| 6885 volatility | |
|---|---|
| 6885 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6885 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6885's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Chyi Shyu Wen | www.brimbiotech.com |
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company’s lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis.
BRIM Biotechnology, Inc. Fundamentals Summary
| 6885 fundamental statistics | |
|---|---|
| Market cap | NT$3.61b |
| Earnings (TTM) | -NT$688.02m |
| Revenue (TTM) | NT$90.00k |
Over9,999x
P/S Ratio-5.2x
P/E RatioIs 6885 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6885 income statement (TTM) | |
|---|---|
| Revenue | NT$90.00k |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$90.00k |
| Other Expenses | NT$688.11m |
| Earnings | -NT$688.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.94 |
| Gross Margin | 100.00% |
| Net Profit Margin | -764,468.89% |
| Debt/Equity Ratio | 0% |
How did 6885 perform over the long term?
See historical performance and comparison